Found "Health Promotion": 1,004 results
Sort by
Last updated

How can health technology assessment support our response to public health emergencies?

Public health emergencies (PHEs), such as the COVID-19 crisis, are threats to global health and public order. We recommend that countries bolster their PHE responses by investing in health technology assessment (HTA), defined as a systematic process of gathering pertinent information on and evaluati

Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance

The Thai government implemented COVID-19 booster vaccines to prevent morbidity and mortality during the spreading of the Omicron variant. However, little is known about which types of vaccine should be invested in as the booster dose for the Thai population. This study aims to investigate the most c

Health economic evaluations for Indonesia: a systematic review assessing evidence quality and adherence to the Indonesian Health Technology Assessment (HTA) Guideline

The Government of Indonesia implemented health technology assessment (HTA) to ensure quality and cost control in the National Health Insurance Program (Jaminan Kesehatan Nasional/JKN). The current aim of the study was to improve the usefulness of future economic evaluation for resource allocation by

Effectiveness of chatbots on COVID vaccine confidence and acceptance in Thailand, Hong Kong, and Singapore

Chatbots have become an increasingly popular tool in the field of health services and communications. Despite chatbots’ significance amid the COVID-19 pandemic, few studies have performed a rigorous evaluation of the effectiveness of chatbots in improving vaccine confidence and acceptance. In Thaila

How Many People Experience Unsafe Medical Care in Thailand, and How Much Does It Cost under Universal Coverage Scheme?

Adverse events and medical harm comprise major health concerns for people all over the world, including Thailand. The prevalence and burden of medical harm must always be monitored, and a voluntary database should not be used to represent national value. The purpose of this study is to estimate the

Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

Using an experiment among clinical experts to determine the cost and clinical impact of rapid whole exome sequencing in acute pediatric settings

Introduction Genetic disorders in children contribute to acute hospitalizations and mortality. Early diagnosis is critical for better outcomes but difficult to achieve due to atypical presentations for thousands of potential genetic diseases. Next-generation sequencing (NGS) is a precision

Analyses of the return on investment of public health interventions: a scoping review and recommendations for future studies

Abstract Return on investment (ROI) analysis is increasingly being used for evaluating the value for money of public health interventions. Given its potential role for informing health policies, it is important that there is a more comprehensive understanding of ROI analysis within the global

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline

Indonesia issued the 2017 health technology assessment (HTA) guideline to facilitate researchers conducting economic evaluations based on standardised principles. However, our evaluation revealed no significant differences in adherence to its recommendation between HTA studies conducted before and a

Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations

There is a growing demand for public health insurance programmes to reimburse high-cost medicines, including those that do not represent good value-for-money. This demand is likely to inhibit financial sustainability, given the growth of new technologies and public demands for expanded access to car
10 / Page